Hypercalcemia of Malignancy
The most common cause of hypercalcemia in hospitalized patients. "Stones, bones, groans, psychiatric moans." PTH will be SUPPRESSED (unlike primary hyperparathyroidism). Treatment is stepwise: fluids → calcitonin (hours) → bisphosphonate (days). Furosemide for hypercalcemia is outdated.
🔍 Overview
Mechanisms of Malignancy-Related Hypercalcemia
| Mechanism | Frequency | Associated Cancers | Key Lab Finding |
|---|---|---|---|
| PTHrP (Humoral) | ~80% | Squamous cell carcinomas (lung, H&N), renal cell, breast, bladder | PTHrP elevated, PTH suppressed, PO₄ low |
| Osteolytic metastases | ~20% | Breast cancer, multiple myeloma | PTHrP normal, local cytokine release (RANKL, IL-6) |
| 1,25-dihydroxyvitamin D | < 1% | Lymphoma (Hodgkin and non-Hodgkin) | 1,25-vit D elevated (tumor-produced 1-alpha hydroxylase) |
| Ectopic PTH | Very rare | Ovarian, lung small cell (rare) | PTH elevated (from tumor) |
Symptoms -"Stones, Bones, Groans, Psychiatric Moans"
- Stones: Nephrolithiasis, nephrocalcinosis, polyuria (nephrogenic DI from Ca²⁺ → impaired ADH response)
- Bones: Bone pain, pathologic fractures, osteoporosis
- Groans: Abdominal pain, constipation, nausea, vomiting, pancreatitis (rare)
- Psychiatric moans: Confusion, lethargy, depression, psychosis, coma
- Cardiac: Shortened QT interval, bradycardia, AV block (severe)
- Renal: Polyuria → dehydration → worsening hypercalcemia (vicious cycle)
Severity Classification
| Severity | Corrected Ca²⁺ | Approach |
|---|---|---|
| Mild | 10.5–12.0 mg/dL | Oral hydration, monitor, treat underlying malignancy |
| Moderate | 12.0–14.0 mg/dL | IV fluids ± calcitonin + bisphosphonate |
| Severe / Symptomatic | > 14.0 mg/dL or symptomatic | Aggressive IV fluids + calcitonin + bisphosphonate. May need ICU. |
🚨 Management
Stepwise Treatment Protocol
| Step | Intervention | Onset | Details |
|---|---|---|---|
| Step 1: IV NS | Normal Saline 200–300 mL/hr | Immediate | Most patients are severely volume-depleted from hypercalcemia-induced nephrogenic DI (polyuria + poor PO intake). This alone drops Ca by 1–2 mg/dL. Goal: restore euvolemia and enhance renal calcium excretion. |
| Step 2: Calcitonin | Calcitonin (Miacalcin) 4 IU/kg SQ/IM q12h | 4–6 hours | Bridge therapy -works FAST but tachyphylaxis by 48h (receptors downregulate). Drops Ca by ~1–2 mg/dL. Mild side effect: flushing, nausea. Used while waiting for bisphosphonate to kick in. |
| Step 3: Bisphosphonate | Zoledronic acid (Zometa) 4 mg IV over 15 min | 2–4 DAYS | Definitive treatment. Inhibits osteoclast-mediated bone resorption. Effect lasts weeks. Check Cr first -reduce dose if CrCl < 60. Alternative: pamidronate 60–90 mg IV over 2–4h (slower infusion, may be better in renal impairment). |
| Step 4 (Refractory) | Denosumab (Xgeva) 120 mg SQ | Days | For bisphosphonate-refractory hypercalcemia. RANKL inhibitor. Works even in renal failure (not renally cleared, unlike bisphosphonates). Dose on days 1, 8, 15, 29, then monthly. |
Furosemide (Lasix) for hypercalcemia is OUTDATED. Old teaching was "saline + Lasix." Current evidence: Lasix only if volume overloaded. It does not meaningfully lower calcium and risks further dehydration and electrolyte derangements.
Special Situations
- Lymphoma (1,25-vit D mediated): Glucocorticoids (dexamethasone 4 mg IV q6h or equivalent) are effective -they inhibit 1-alpha hydroxylase in tumor cells and decrease 1,25-vit D production.
- Multiple myeloma: Bisphosphonates are standard (both for hypercalcemia and skeletal events). Zoledronic acid or pamidronate.
- Dialysis: If refractory or anuric, hemodialysis with low-calcium dialysate can rapidly lower calcium.
🧪 Workup
Laboratory Workup
- Corrected calcium = measured Ca + 0.8 × (4.0 − albumin). Or check ionized calcium (more accurate, not affected by albumin).
- PTH -should be SUPPRESSED (< 20 pg/mL) in malignancy. If PTH is elevated → think primary hyperparathyroidism (even in cancer patients -can coexist).
- PTHrP -elevated in humoral hypercalcemia of malignancy (80% of cases). Order if PTH suppressed.
- 1,25-dihydroxyvitamin D -elevated in lymphoma. Order if PTHrP is normal and PTH is suppressed.
- 25-hydroxyvitamin D -to rule out exogenous vitamin D toxicity.
- Phosphate -low in PTHrP-mediated (PTHrP causes renal phosphate wasting, same as PTH).
- BMP -Cr (renal function), K⁺, Mg²⁺.
- ECG -shortened QT interval is the classic finding. Also watch for bradycardia, AV block.
- SPEP/UPEP -if myeloma suspected.
💊 Medications
Hypercalcemia Medications
| Drug | Dose | Onset | Duration | Key Notes |
|---|---|---|---|---|
| Normal Saline | 200–300 mL/hr | Immediate | During infusion | First-line. Volume expansion + calciuresis. Drops Ca ~1–2 mg/dL. Watch for volume overload. |
| Calcitonin (Miacalcin) | 4 IU/kg SQ/IM q12h | 4–6 hours | 48h (tachyphylaxis) | Bridge only. Drops Ca ~1–2 mg/dL. Safe but temporary. Tachyphylaxis limits use beyond 48h. |
| Zoledronic acid (Zometa) | 4 mg IV over 15 min | 2–4 days | Weeks | Definitive treatment. Check CrCl -reduce dose if < 60. Risk: osteonecrosis of jaw (rare), renal toxicity. |
| Pamidronate | 60–90 mg IV over 2–4h | 2–4 days | Weeks | Alternative to zoledronic acid. Longer infusion but may be better tolerated in renal impairment. |
| Denosumab (Xgeva) | 120 mg SQ | Days | Weeks | Bisphosphonate-refractory cases. RANKL inhibitor. Works in renal failure. Risk: hypocalcemia, ONJ. |
| Glucocorticoids | Dexa 4 mg IV q6h | Days | During treatment | Effective for lymphoma and granulomatous disease (1,25-vit D mediated). Not effective for PTHrP-mediated. |
📋 On Rounds
Why is PTH suppressed in hypercalcemia of malignancy?
In malignancy-related hypercalcemia, the elevated calcium provides negative feedback to the parathyroid glands via the calcium-sensing receptor (CaSR). Since the hypercalcemia is driven by PTHrP, osteolytic metastases, or tumor-produced 1,25-vit D -NOT by the parathyroid glands -the glands appropriately suppress PTH secretion. This is the key lab distinction: Malignancy → PTH LOW, PTHrP HIGH.
What is tachyphylaxis with calcitonin, and how does it affect your treatment plan?
Tachyphylaxis = diminishing response to a drug after repeated doses. Calcitonin works by inhibiting osteoclast activity and promoting renal calcium excretion. However, calcitonin receptors downregulate within 48 hours of continuous exposure, and the calcium-lowering effect is lost. This is why calcitonin is a bridge therapy only -it buys you 24–48h of calcium lowering while you wait for the bisphosphonate (zoledronic acid)
When would you use denosumab instead of zoledronic acid?
Denosumab (Xgeva) is a RANKL inhibitor (monoclonal antibody) used for hypercalcemia refractory to bisphosphonates. Key advantages: (1) Not renally cleared -safe in renal failure (CrCl < 30), whereas bisphosphonates require dose adjustment or are contraindicated. (2) Bisphosphonate-refractory -if Ca remains elevated after adequate bisphosphonate trial. Disadvantages: (1) Risk of rebound hypercalcemia if discontinued abruptly.
Clinical Examples
📋 Case 1, Hypercalcemia of Malignancy (PTHrP-Mediated)
Patient: 62M with 30-pack-year smoking history. Confusion, polyuria, constipation. Ca 15.2, PTH < 5, PTHrP 14.8 pmol/L (elevated). CT chest: 5 cm RUL mass with hilar LAD. Cr 2.1.
Key findings: Severe hypercalcemia of malignancy via PTHrP from probable squamous cell lung cancer. Suppressed PTH confirms non-parathyroid etiology. Dehydration worsening renal function.
Management:
- NS 200-300 mL/hr (aggressive rehydration, these patients are profoundly volume-depleted)
- Calcitonin 4 IU/kg SQ q12h (bridge, works within hours but tachyphylaxis by 48h)
- Zoledronic acid 4 mg IV over 15 min (definitive, onset 2-4 days, lasts 2-4 weeks)
- No furosemide unless volume overloaded (old teaching of "lasix for hypercalcemia" is outdated and harmful in dehydrated patients)
- Oncology consult for biopsy and staging of lung mass
Teaching point: Calcitonin is a bridge, not a treatment. Its effect wears off in 48h due to receptor tachyphylaxis. Zoledronic acid is the definitive agent but takes 2-4 days, hence the bridge strategy.
📋 Case 2, Severe Hypercalcemia with Renal Failure
Patient: 71F with metastatic breast cancer. Ca 17.8, Cr 4.2 (baseline 1.0), AMS. PTH < 3. No urine output × 6h despite 2L NS bolus. ECG: short QT.
Key findings: Life-threatening hypercalcemia with oliguric AKI. Bisphosphonates relatively contraindicated at CrCl < 30. Need alternative approach.
Management:
- Continue aggressive IVF, target UOP > 200 mL/hr if achievable
- Calcitonin 4 IU/kg SQ q12h (immediate bridge)
- Denosumab 120 mg SQ (not renally cleared, safe in renal failure, preferred over zoledronic acid here)
- If refractory: emergent hemodialysis with low-calcium dialysate (can drop Ca 3-4 mg/dL per session)
- Telemetry monitoring, QT shortening, arrhythmia risk at Ca > 14
Teaching point: Denosumab is the rescue agent when bisphosphonates are contraindicated (renal failure) or have failed. Key risk: rebound hypercalcemia if stopped abruptly, always plan for ongoing dosing or transition.
📋 Case 3, Granulomatous Disease Hypercalcemia
Patient: 38F with known sarcoidosis. Ca 12.6, PTH 6 (suppressed), PTHrP normal, 1,25-dihydroxy vitamin D 88 pg/mL (elevated), 25-OH vitamin D 22 (normal). Bilateral hilar LAD on CXR.
Key findings: Granulomatous hypercalcemia, activated macrophages in granulomas express 1-alpha-hydroxylase, converting 25-OH vitamin D → 1,25-dihydroxy vitamin D (calcitriol) autonomously. Not PTH-driven.
Management:
- IV hydration (NS 150-200 mL/hr)
- Prednisone 20-40 mg daily (first-line, glucocorticoids inhibit 1-alpha-hydroxylase in macrophages)
- Expect calcium normalization within 3-5 days of steroids
- Avoid vitamin D supplementation and excessive sun exposure (fuel the pathway)
- Treat underlying sarcoidosis per pulmonology
Teaching point: Granulomatous hypercalcemia (sarcoidosis, TB, fungal) responds to glucocorticoids because steroids suppress macrophage 1-alpha-hydroxylase. This is the one form of hypercalcemia where steroids are first-line, not bisphosphonates.
Monitoring Parameters
| Parameter | Frequency | Target / Action |
|---|---|---|
| Ionized calcium or corrected Ca | q6–8h until stable | Trend toward normalization. Recheck 2–4 days after bisphosphonate. |
| BMP (Cr, K⁺, Mg²⁺, PO₄) | q12h initially | Cr for AKI/renal recovery. Watch for hypokalemia, hypomagnesemia, hypophosphatemia with fluids. |
| Fluid balance / I&Os | Strict | Maintain euvolemia. Aggressive IVF but watch for volume overload (especially if cardiac history). |
| ECG | Admission + PRN | Shortened QT, bradycardia, AV block. |
| Mental status | q shift | Improvement in confusion/lethargy as calcium normalizes. |
Monitoring Parameters
| Parameter | Frequency | Target / Action |
|---|---|---|
| Vitals | q4h floor, q1–2h ICU | HR, BP, RR, SpO₂, Temp -notify for significant deviations |
| Labs (BMP, CBC) | Daily AM or as indicated | Trend Cr, K⁺, WBC, Hgb -adjust treatment based on trajectory |
| Disease-specific markers | Per clinical context | See Overview and Management tabs for condition-specific targets |
| I&Os | Strict if volume-sensitive | UOP ≥ 0.5 mL/kg/hr. Net fluid balance guides diuresis or resuscitation. |
| Telemetry | Continuous if indicated | Arrhythmia detection. Discontinue when no longer indicated (reduces alarm fatigue). |
| Clinical response | Each assessment | Symptom improvement, functional status, appetite, mental status -the exam matters more than labs |
Don't just order labs -act on them. Every lab should have a clear clinical question. If you wouldn't change management based on the result, don't order it.
⚡ Summary
Hypercalcemia of Malignancy -Key Points
Recognize It
Stones, bones, groans and psychiatric moans: kidney stones and polyuria, bone pain, constipation, nausea and abdominal pain, and confusion progressing to coma. It is the commonest cause of hypercalcemia in hospitalized patients, and the severity of symptoms depends on how fast it rose as much as on the number.
Correct the Number Before Acting On It
Add 0.8 mg/dL for every 1 g/dL the albumin sits below 4, or measure ionized calcium directly. Cancer patients are frequently hypoalbuminemic, so an uncorrected total calcium understates the true level and delays treatment.
A Suppressed PTH Is the Discriminator
PTH is suppressed in malignancy and inappropriately normal or high in primary hyperparathyroidism. That single test splits the differential. Then check PTHrP and 1,25-dihydroxyvitamin D to identify which malignant mechanism is operating.
Know Which Mechanism You Are Treating
PTHrP-mediated humoral hypercalcemia (about 80%), classically squamous cell carcinoma, renal cell and breast. Local osteolysis from bone metastases and myeloma. Calcitriol-mediated, from lymphoma and granulomatous disease, where 1-alpha-hydroxylase in the tumor activates vitamin D. The calcitriol type is the one that responds to steroids, and it is the one where vitamin D supplementation makes things worse.
Fluids First, and Generously
Isotonic saline, typically 200 to 300 mL/h initially, titrated to a urine output of 100 to 150 mL/h. These patients are profoundly volume-depleted from the calcium-induced nephrogenic diabetes insipidus, and restoring glomerular filtration is what starts the calcium falling within hours.
Calcitonin Bridges, Bisphosphonate Treats
Calcitonin 4 units/kg SC or IM q12h works within 4 to 6 h but tachyphylaxis develops in 48 h, so it is a bridge and nothing more. Zoledronic acid 4 mg IV is the definitive agent but takes 2 to 4 days to work, which is exactly the gap calcitonin covers. Give both at the start rather than in sequence.
Furosemide Is Outdated
The old teaching of saline plus Lasix is wrong. Loop diuretics do not meaningfully lower calcium and they worsen the dehydration that is driving it. Use them only if the patient becomes volume overloaded during fluid resuscitation, and then for that reason, not for the calcium.
Match the Refractory Options to the Situation
Denosumab when renal function precludes a bisphosphonate, or for bisphosphonate-refractory hypercalcemia; it is not renally cleared, but it can cause prolonged hypocalcemia. Steroids for calcitriol-mediated hypercalcemia (lymphoma, sarcoidosis). Dialysis for severe, refractory or oliguric cases. Treat the cancer, since nothing else is durable, and recognize what the diagnosis signals: hypercalcemia of malignancy carries a poor prognosis and is a prompt for a goals-of-care conversation.
📄 One Pager
Text version
HEME/ONC · One Pager
Hypercalcemia of Malignancy
The tumor drives calcium up and the parathyroids appropriately shut off, so PTH is SUPPRESSED; treat in sequence, fluids for volume, calcitonin as the fast bridge, a bisphosphonate as the definitive agent.
Mechanisms, Most Common First
- PTHrP, humoral (~80%), in squamous cell carcinomas (lung, head and neck), renal cell, breast, bladder. PTHrP elevated, PTH suppressed, phosphate LOW, because PTHrP causes renal phosphate wasting exactly as PTH does.
- Osteolytic metastases (~20%), in breast cancer and multiple myeloma. PTHrP is normal here: calcium comes from local cytokine release (RANKL, IL-6) dissolving bone directly, which is why bone-directed therapy is the answer.
- 1,25-dihydroxyvitamin D mediated (< 1%), in lymphoma (Hodgkin and non-Hodgkin). Tumor cells make their own 1-alpha hydroxylase, so 1,25-vitamin D is elevated. This is the subtype that responds to steroids.
- Ectopic PTH (very rare), ovarian and small cell lung. PTH is elevated because the tumor itself secretes it, the one malignant mechanism that breaks the "PTH is suppressed" rule.
- Why the mechanism matters: it decides whether the definitive drug is a bisphosphonate, denosumab, or a glucocorticoid.
Presentation & Severity
- Stones: nephrolithiasis, nephrocalcinosis, and polyuria from a nephrogenic DI (calcium impairs the renal response to ADH).
- Bones: bone pain, pathologic fractures, osteoporosis.
- Groans: abdominal pain, constipation, nausea, vomiting, rarely pancreatitis.
- Psychiatric moans: confusion, lethargy, depression, psychosis, coma.
- Cardiac: shortened QT interval (the classic ECG finding), bradycardia, AV block when severe.
- The vicious cycle: polyuria causes dehydration, dehydration reduces renal calcium clearance, calcium climbs further. This is why volume comes first in treatment.
- Mild, corrected Ca 10.5-12.0: oral hydration, monitor, treat the underlying malignancy.
- Moderate, 12.0-14.0: IV fluids ± calcitonin plus a bisphosphonate.
- Severe, > 14.0 or symptomatic: aggressive IV fluids plus calcitonin plus bisphosphonate; may need ICU.
Management, Step by Step
1
Normal saline 200-300 mL/hr, effect immediate. These patients are severely volume-depleted from hypercalcemia-induced nephrogenic DI plus poor oral intake. Restoring euvolemia enhances renal calcium excretion and drops calcium 1-2 mg/dL by itself, which is why nothing else works properly until this is done.
2
Calcitonin 4 IU/kg SQ or IM q12h, onset 4-6 hours. The only agent that works fast, so it bridges the gap while the bisphosphonate takes effect. Drops calcium ~1-2 mg/dL. Tachyphylaxis by 48h as receptors downregulate, so it is a bridge and never the plan.
3
Zoledronic acid 4 mg IV over 15 min, onset 2-4 DAYS, lasts weeks. The definitive treatment: it inhibits osteoclast-mediated bone resorption, which is the actual source of the calcium. Check creatinine first and reduce the dose if CrCl < 60. Alternative: pamidronate 60-90 mg IV over 2-4h, a slower infusion that may be better tolerated in renal impairment.
4
Refractory or renal failure: denosumab 120 mg SQ, onset days. A RANKL inhibitor that works even in renal failure because it is not renally cleared, unlike bisphosphonates. Dose on days 1, 8, 15, 29, then monthly. Plan continued dosing, since abrupt discontinuation causes rebound hypercalcemia.
5
Do NOT give furosemide reflexively. The old "saline plus Lasix" teaching is outdated: it does not meaningfully lower calcium and worsens the dehydration that is driving the problem. Use it only if the patient is genuinely volume overloaded.
Key Drugs
Normal saline200-300 mL/hr. First-line: volume expansion plus calciuresis drops Ca ~1-2 mg/dL. Watch for volume overload in cardiac patients.
Calcitonin (Miacalcin)4 IU/kg SQ or IM q12h. Onset 4-6 h, useful for only ~48h before tachyphylaxis. Drops Ca ~1-2 mg/dL. Mild flushing and nausea.
Zoledronic acid (Zometa)4 mg IV over 15 min. Onset 2-4 days, lasts weeks. Definitive agent. Check CrCl and reduce if < 60. Risks: renal toxicity, rare osteonecrosis of the jaw.
Pamidronate60-90 mg IV over 2-4h. Same onset and duration as zoledronic acid; the longer infusion may be better tolerated in renal impairment.
Denosumab (Xgeva)120 mg SQ. RANKL inhibitor for bisphosphonate-refractory disease or renal failure, since it is not renally cleared. Risks: hypocalcemia, osteonecrosis of the jaw, rebound hypercalcemia if stopped.
GlucocorticoidsDexamethasone 4 mg IV q6h. Works only in the 1,25-vitamin D mediated forms (lymphoma, granulomatous disease) by inhibiting 1-alpha hydroxylase. Not effective for PTHrP-mediated disease.
Monitoring
- Ionized or corrected calcium q6-8h until stable, then recheck 2-4 days after the bisphosphonate, which is when it actually starts working and when you decide whether denosumab is needed.
- BMP q12h initially: creatinine for AKI and renal recovery, and watch for the hypokalemia, hypomagnesemia, and hypophosphatemia that aggressive fluids produce.
- Strict intake and output. You are deliberately running fluids hard, so volume overload is the predictable complication, especially with cardiac history.
- ECG on admission and PRN: shortened QT, bradycardia, and AV block are the arrhythmia signals, and the risk rises above a calcium of 14.
- Mental status each shift. Clearing confusion is the clinical endpoint that tells you the number is translating into benefit.
- Corrected calcium = measured Ca + 0.8 × (4.0 − albumin), or use ionized calcium, which albumin does not distort.
Pitfalls
- Reaching for furosemide. Outdated teaching: it does not meaningfully lower calcium and it deepens the dehydration that caused the hypercalcemia. Only for true volume overload.
- Treating calcitonin as the therapy. Tachyphylaxis at 48h means the calcium rebounds unless a bisphosphonate or denosumab was started alongside it on day one.
- Giving zoledronic acid without checking renal function. Reduce the dose if CrCl < 60, and reach for denosumab instead when the kidney is failing.
- Stopping denosumab abruptly. Rebound hypercalcemia follows; always plan ongoing dosing or a deliberate transition.
- Assuming every hypercalcemia in a cancer patient is paraneoplastic. If PTH is elevated, think primary hyperparathyroidism, which can coexist with malignancy and needs an entirely different workup.
- Giving steroids for PTHrP-mediated hypercalcemia. They only work when the driver is tumor or macrophage 1,25-vitamin D production.
- Expecting a bisphosphonate to work overnight. Onset is 2-4 days, which is the entire reason the calcitonin bridge exists.
Special Situations
- Lymphoma (1,25-vitamin D mediated): glucocorticoids, dexamethasone 4 mg IV q6h or equivalent, because they inhibit 1-alpha hydroxylase in the tumor cells and shut off calcitriol production at the source.
- Granulomatous disease (sarcoidosis, TB, fungal): prednisone 20-40 mg daily is first-line, since activated macrophages in granulomas autonomously convert 25-OH vitamin D to calcitriol. Expect normalization within 3-5 days, and avoid vitamin D supplements and heavy sun exposure, which fuel the pathway. This is the one form of hypercalcemia where steroids beat bisphosphonates.
- Multiple myeloma: bisphosphonates are standard, treating both the hypercalcemia and the skeletal-related events. Zoledronic acid or pamidronate.
- Refractory or anuric: hemodialysis with low-calcium dialysate rapidly lowers calcium, dropping it 3-4 mg/dL per session when fluids are not an option.
Workup, in Sequence
- Corrected or ionized calcium first, to confirm the calcium is genuinely high and not an albumin artifact.
- PTH: should be SUPPRESSED (< 20 pg/mL) in malignancy, because high calcium feeds back on the parathyroid calcium-sensing receptor and the glands respond appropriately. An elevated PTH points to primary hyperparathyroidism instead.
- PTHrP next if PTH is suppressed, since it is the mechanism in 80% of cases.
- 1,25-dihydroxyvitamin D if PTHrP is normal and PTH is suppressed, which identifies the lymphoma and granulomatous group that needs steroids.
- 25-hydroxyvitamin D to rule out exogenous vitamin D toxicity as the cause.
- Phosphate: low in PTHrP-mediated disease, because PTHrP wastes phosphate at the kidney just as PTH does.
- BMP for creatinine, K⁺, and Mg²⁺; ECG for the shortened QT; SPEP/UPEP if myeloma is suspected.
Related Topics
Acute Leukemia (AML / ALL)AmyloidosisAnemia WorkupAnemia WorkupAnticoagulation ManagementChemotherapy Toxicities